| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8444085 | European Journal of Cancer | 2013 | 10 Pages |
Abstract
In this largest SIOP cohort described so far, overall outcome of CCSK is reasonable, although treatment of young and advanced-stage disease patients is challenging. As further intensification of treatment is hampered by direct and late toxicity, future directions should include the development of targeted therapy based on specific molecular aberrations of CCSK.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
R. Furtwängler, S.L. Gooskens, H. van Tinteren, J. de Kraker, G. Schleiermacher, C. Bergeron, B. de Camargo, T. Acha, J. Godzinski, B. Sandstedt, I. Leuschner, G.M. Vujanic, R. Pieters, N. Graf, M.M. van den Heuvel-Eibrink,